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Abstract
Objective: Systematic investigation of individuals with intellectual disability
after genetic diagnosis can illuminate specific phenotypes and mechanisms
relevant to common neurodevelopmental disorders. We report the neurological,
cognitive and neuroanatomical characteristics of nine males from three families
with loss-of-function mutations in ZDHHC9 (OMIM #300799). Methods: All
known cases of X-linked intellectual disability (XLID) due to ZDHHC9 muta-
tion in the United Kingdom were invited to participate in a study of neurocog-
nitive and neuroimaging phenotypes. Results: Seven out of nine males with
ZDHHC9 mutations had been diagnosed with epilepsy, exceeding epilepsy risk
in XLID comparison subjects (P = 0.01). Seizure histories and EEG features
amongst ZDHHC9 mutation cases shared characteristics with rolandic epilepsy
(RE). Specific cognitive deficits differentiated males with ZDHHC9 mutations
from XLID comparison subjects and converged with reported linguistic and
nonlinguistic deficits in idiopathic RE: impaired oromotor control, reduced ver-
bal fluency, and impaired inhibitory control on visual attention tasks. Consis-
tent neuroanatomical abnormalities included thalamic and striatal volume
reductions and hypoplasia of the corpus callosum. Interpretation: Mutations in
ZDHHC9 are associated with susceptibility to focal seizures and specific cogni-
tive impairments intersecting with the RE spectrum. Neurocognitive deficits are
accompanied by consistent abnormalities of subcortical structures and inter-
hemispheric connectivity. The biochemical, cellular and network-level mecha-
nisms responsible for the ZDHHC9-associated neurocognitive phenotype may
be relevant to cognitive outcomes in RE.
Introduction
Genetic diagnosis is now possible for an increasing
proportion of individuals with neurodevelopmental disor-
ders, including intellectual disability and childhood
epilepsies. Postgenomic investigation of rare, recurrent
Mendelian disorders has the potential to identify specific
phenotypic correlates and highlight novel neurodevel-
opmental mechanisms relevant to common, complex
conditions. Considerable progress has been made in iden-
tifying genes responsible for X-linked intellectual disability
(XLID), and more than one hundred recurrent causes
have been reported.1,2 Inherited mutations in ZDHHC9
were identified in four of two hundred and fifty families
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with XLID via a systematic screen of coding exons and
splice junctions of all X chromosome genes.3 ZDHHC9
encodes a palmitoylation enzyme involved in reversible
lipid modification and cyclical intracellular localization of
neuronal and non-neuronal substrates.4 Recent functional
analysis confirms that all XLID-associated mutations
reduce ZDHHC9 enzymatic activity5 however, the cellular
and developmental mechanisms leading from reduced
palmitoylation to XLID are not understood.
In common with many gene discovery studies, detailed
neurological histories, cognitive evaluations and neuroi-
maging were not available at the time of the initial
ZDHHC9 mutations report. To address this limitation,
we carried out a neurocognitive phenotyping study of all
UK-based cases diagnosed with mutations in ZDHHC9,
the results of which are reported in the current paper.
The first phase of this study uncovered evidence that
ZDHHC9 mutations are associated with susceptibility to
focal seizures sharing features with rolandic epilepsy (RE;
also known as Benign Childhood Epilepsy with Centro-
Temporal Spikes, BECTS), the most frequently diagnosed
epilepsy syndrome of childhood.6,7 Having identified this
unexpected association, we posed two targeted hypothe-
ses. First, we predicted that males with ZDHHC9 muta-
tions might share specific cognitive characteristics with
RE8,9 and that these specific deficits would discriminate
ZDHHC9 mutation cases from IQ-matched comparison
subjects with mutations in other XLID genes. We assessed
speech and language functions known to be impaired in a
significant proportion of individuals with RE and to
persist after seizure remission.10–12 We also assessed
aspects of nonlinguistic attention, because impairments in
attention have been consistently reported in RE and may
reflect altered network maturation relevant to long-term
cognitive outcomes.13,14 Second, we predicted that
ZDHHC9 mutations might be associated with consistent
structural brain abnormalities, in contrast to heteroge-




Ethical approval was granted by the Cambridge Central
Research Ethics Committee (11/0330/EE). Eligible partici-
pants were males >6 years in whom a pathogenic variant
in an XLID gene had been identified (http://gold-
study.cimr.cam.ac.uk/). The ZDHHC9 case group com-
prised nine males from GOLD families 31, 152 and 576,3
age range 8.6–41.3 years (mean 27, SD 14). Neurological
and behavioral characteristics were compared to 26 males
with XLID and pathogenic mutations in other published
genes (XLID control group), age range 9.6–54 years
(mean 28, SD 13): AP1S2 (n = 3), CUL4B (n = 5), DLG3
(n = 3), HUWE1 (n = 3), PAK3 (n = 5), PTCHD1
(n = 1), SYP (n = 2), UBE2A (n = 1), SLC9A6 (n = 2),
OPHN1 (n = 1). Cognitive testing was carried out for
ZDHHC9 cases (n = 8) and XLID controls (n = 9)
matched in age (Mann–Whitney U P = 0.236) and sever-
ity of ID (Vineland Adaptive Behaviour composite score,
Mann–Whitney U P = 0.195). Research MRI was carried
out for ZDHHC9 cases (n = 7) and individually age-
matched (2 years) male controls with no history of neu-
rological illness or cognitive impairment (n = 7).
Neurological and behavioral assessments
Structured medical interview was supplemented by review
of medical records and clinical investigations including
EEG where available. Epilepsy phenotypes were classified
according to ILAE guidance.16 Neurological examination
was carried out by a qualified pediatrician and video-
taped for later review. Behavioral questionnaires were
completed by a close family member or professional carer.
Global ability and adaptive functions were assessed via
Vineland Adaptive Behaviour scales,17 everyday language
skills via age-appropriate Communication Checklists,18,19
and behavioral problems via age-appropriate Develop-
mental Behavior Checklists.20,21
Cognitive testing
Assessment tools were selected to be comparable to previ-
ous investigations of idiopathic RE, and appropriate for
children and adults with ID. The protocol tested general
intellectual abilities (WASI-II22), auditory processing (Fil-
tered Words, Competing Words from SCAN-A23), recep-
tive language (Word Classes, Concepts and Directions
from CELF-IIIR24) and expressive language (Rapid Auto-
matic Naming, Formulating Sentences from CELF-IIIR19).
Speech and nonspeech oromotor functions were assessed
via the Verbal Motor Production Assessment for Children
(VMPAC).25 VMPAC assessments were video-rated by
two speech and language pathologists blind to genetic
diagnosis.
Three nonlinguistic visual attention tasks (detection,
oddball, Go/NoGo) analogous to continuous perfor-
mance tests were administered according to a method
previously described.26 In each task, participants are
instructed to respond via a button box as quickly as pos-
sible to the same easy-to-discriminate visual targets
(high-contrast Gabor patches) presented on a laptop
computer. Each task begins with slow practice trials fol-
lowed by real-time practice and 1 min test blocks with
fifteen targets per block. Interstimulus interval was fixed
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at 300 msec, stimulus duration 50 msec. Auditory feed-
back is provided to reinforce every correct response. In
the detection task, targets are randomly presented within
a stream of central fixation crosses. In the oddball task,
targets are randomly presented within a stream of non-
target stimuli (low contrast Gabor patches). In the Go/
NoGo task, Go stimuli (low frequency Gabor patch,
50%) and NoGo stimuli (high frequency Gabor patch,
50%) are randomly presented within a stream of central
fixation crosses. Outcome measures for all tasks were
omission errors (one minus correct responses to target
stimuli), commission errors (anticipatory responses and
responses to nontarget stimuli), and median reaction
times to target stimuli.
Statistical analysis
Questionnaire scores were standardized to published nor-
mative data. Raw scores on neuropsychological measures
were transformed to study-specific Z scores. Behavioral
data were checked for normality of distributions prior to
parametric or nonparametric analysis. Full-scale IQ was
included as a covariate in multivariate analyses.
Neuroimaging acquisition and analysis
T1-weighted MP-RAGE, T2-weighted and FLAIR
sequences were obtained on the Siemens 3 T Tim Trio
system at the MRC Cognition and Brain Sciences Unit,
Cambridge U.K. Qualitative reporting was carried out by
a consultant neuroradiologist blind to genetic diagnosis.
Regional volumetric analysis was carried out via voxel-
based morphometry (VBM). T1-weighted images under-
went spatial preprocessing using the VBM8 Toolbox
(Christian Gaser) in SPM8 (www.fil.ion.ucl.ac.uk/spm).
Images were Dartel-realigned, normalized to the MNI
template, segmented (modulated, affine and nonlinear),
and smoothed at 8 mm Full Width at Half Maximum
(FMHW) for gray matter (GM) and 12 mm FMHW for
white matter (WM). Preprocessed images were visually
inspected prior to case–control comparison, with co-vari-
ation for age and global GM or WM (voxel-wise tissue
classification relative threshold 0.8, cluster threshold
k = 50, statistical threshold P < 0.05 with family-wise
error correction). Global tissue volumes (GM, WM, cere-
brospinal fluid, intracranial volume) were extracted dur-
ing preprocessing.
Corpus callosum midsagittal areas and subcortical
structure volumes were traced in MRICron (Chris Ror-
den, www.mccauslandcenter.sc.edu/mricro/) using a
graphics tablet. Landmarks for tracing the thalamus, cau-




All subjects were in good health at the time of assessment,
with no reported deteriorations in neurological or cognitive
function. A significantly higher proportion of ZDHHC9
cases (7/9, 77.8%) than XLID controls (7/26, 26%) had
received a diagnosis of epilepsy, according to documented
local clinician evaluations of witnessed seizures and EEG
(Pearson Chi-Square 7.2, P = 0.01). Seizure characteristics
of ZDHHC9 cases are described in Table S1, and EEG fea-
tures are illustrated for two cases in Figure 1. Seizures were
brief (usually lasting several minutes) and self-terminating,
occurring only or predominantly at night. Seizures were
characterized by involuntary, sustained facial motor activity
and speech arrest, with or without upper limb involvement,
with secondary generalization in some cases. In one case,
only generalized seizures were reported, however motor
activity at onset of seizures had not been observed and the
participant was not able to recollect preemptory symptoms,
a limitation noted previously in idiopathic RE.28 Seizure
onset was during midchildhood with remission during ado-
lescence in all but one case (onset of focal seizures reported
in early adulthood). One case had an atypically severe sei-
zure history, presenting with an episode of status epilepti-
cus after which he suffered from frequent focal seizures,
infrequent brief generalized seizures, and night-time
screaming episodes thought to be seizure-related. His sei-
zures remitted by midadolescence. This individual mani-
fested severe developmental delay with no regression, and
severe intellectual disability with no speech.
Behavioral questionnaires
8/9 ZDHHC9 cases had mild or moderate ID and only 1/9
case had severe ID (Vineland Adaptive Behavior Composite
range 20–71, mean 57, SD 15). 13/26 XLID controls had
mild or moderate ID and 13/26 had severe or profound ID
(Vineland ABC range 20–67, mean 40, SD 17). Hence,
ZDHHC9 cases had significantly milder global impairment
than XLID controls on average (Mann–Whitney U
P = 0.022). ZDHHC9 cases showed prominent impair-
ments in communication and motor abilities, not differing
from XLID controls in these domains (Mann–Whitney U
communication: P = 0.20; motor: P = 0.20) despite signifi-
cantly stronger social and practical skills (Mann–Whitney
U: socialization P = 0.003; daily living skills P = 0.019).
Vineland communication subdomain scores indicated that
the ZDHHC9 case group had better receptive ability than
expressive and written abilities, whilst XLID controls had
better expressive ability than receptive and written abilities
(main effect of group F1,21 = 0.88 P = 0.36, group 9
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subdomain interaction F2,42 = 3.3 P = 0.047). There was
no difference between groups in the profile of expressive
impairments reported via Communication Checklists
(main effect of group F1,21 = 0.43, P = 0.52, group 9 sub-
domain interaction F2,42 = 1.9 P = 0.16). There were no
differences between groups in rates of behavioral problems.
Cognitive testing
ZDHHC9 cases and XLID controls who participated in
cognitive testing were matched on verbal IQ and differed
marginally on performance IQ and full scale IQ (FSIQ)
(higher scores in ZDHHC9 cases). After co-variation for
FSIQ, no significant differences between ZDHHC9 cases
and XLID controls were observed on tests of auditory
processing, receptive language functions, or sentence pro-
duction (Table 1).
The Rapid Automatic Naming test from CELF-IIIR
highlighted verbal fluency problems amongst the
ZDHHC9 group not shared with XLID controls. Cases
demonstrated a range of difficulties on this task including
delayed initiation of responses, articulation problems, and
Figure 1. Clinical EEG recordings for two males with ZDHHC9 mutations. (A) Recording at age 4 years (Case #8) to investigate suspected
seizures, off anti-epileptic medication. Intermittent diphasic sharp waves, synchronous in left temporal and left central leads. (B) Recording at age
9 years (Case #7) to investigate suspected seizures, off anti-epileptic medication. Clusters of raised voltage diphasic sharp waves are maximal over
the centro-parietal regions, more extensive on the left than right side.
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difficulty inhibiting prior responses. For the color naming
subtask, which all subjects could complete, the ZDHHC9
case group took significantly longer than XLID controls
to name all stimuli (Mann–Whitney U P = 0.045), with
no difference in number of correctly named items.
The VMPAC assessment highlighted significant oromo-
tor difficulties for the ZDHHC9 group in comparison to
XLID controls, affecting oral control, sequencing, voice
characteristics and connected speech (main effect of
group F1,10 = 8.3, P = 0.016, group 9 subscale interac-
tion F1,10 = 0.17, P = 0.92). For oral control scores, the
ZDHHC9 group performed more poorly than XLID con-
trols on both speech and nonspeech items (main effect of
group F1,10 = 4.37, P = 0.06; post hoc analysis speech
items F1,10 = 3.34, P = 0.09, nonspeech items F1,10 = 3.02,
P = 0.11). For sequencing scores, there was no significant
difference between groups (F1,10 = 2.46, P = 0.15) but
post hoc analysis suggests that the ZDHHC9 group is
impaired in sequencing speech sounds (F1,10 = 4.62,
P = 0.06) but not sequencing of nonspeech movements
(F1,10 = 1.94, P = 0.19).
On visual attention tasks, the ZDHHC9 group demon-
strated lower omission and higher commission rates
across all visual attention tasks, indicative of reduced
inhibitory control (Fig. 2). On the Go/NoGo task, the
case group correctly responded to targets more often than
controls, but were less successful at inhibiting responses
to distractors within the Go/NoGo task main effect of
group F1,12 = 0.76, P = 0.42, group 9 error-type
F1,12 = 3.7, P = 0.08; post hoc analysis omission errors
F1,10 = 1.96, P = 0.19, commission errors F1,10 = 3.55,
P = 0.08). There was no differences between groups in
speed of responding (F1,12 = 0.26, P = 0.63, group 9 task
F1,12 = 0.8, P = 0.93), indicating that generalized motor
differences do not underlie case-control differences in
attentional performance.
Neuroimaging
Qualitative rating blind to diagnosis identified global or
segmental hypoplasia of the corpus callosum in seven
ZDHHC9 mutation cases, global cerebral volume loss in
five cases, ventricular enlargement in six cases and cere-
bellar vermis volume reduction in one case (Fig. 3). No
focal parenchymal anomalies were noted. None of these
features was present in any healthy age-matched compari-
son subject. Hypoplasia of the corpus callosum was a sta-
ble phenomenon for one case with clinical neuroimaging
available at multiple ages (6, 10 and 13 years) and was
present prior to the onset of seizures in two cases scanned
during early childhood.
Quantitative comparison indicated no significant differ-
ences in intracerebral volume (P = 1.0) or GM volume
(Mann–Whitney U P = 0.62) but a trend toward reduced
WM volume (P = 0.13) and increased cerebrospinal fluid
volume (P = 0.07) in the case group. VBM analysis
(Fig. 4) identified significant bilateral GM reductions in
the thalamus. At uncorrected statistical threshold, GM
reductions in the left caudate were also seen. No areas of
cortical GM difference survived correction for multiple
Table 1. Standardized cognitive assessments.
Domain (standardized battery) Task
ZDHHC9 cases, n = 8,
mean (SD)
XLID controls, n = 9,
mean (SD) ANOVA, F (P)
General cognitive ability (WASI-II) Full scale IQ (FSIQ) 65 (6) 57 (9) 5.4 (0.04)
Perceptual reasoning index 67 (5) 59 (11) 3.7 (0.07)
Verbal comprehension index 64 (6) 58 (11) 2.2 (0.16)
Auditory processing (SCAN-A)1 Filtered words 0.06 (0.67) 0.04 (1.61) 0.01 (0.9)2
Competing words 0.1 (0.92) 0.26 (1.38)
Oromotor function (VMPAC)1 Focal oral control 0.34 (1.1) 0.53 (0.61) 8.3 (0.016)2
Sequencing 0.13 (0.91) 0.21 (1.21)
Connected speech 0.34 (0.92) 0.55 (0.96)
Quality of speech 0.33 (1.1) 0.53 (0.53)
Receptive language (CELF-IIIR)1 Concepts and directions 0.13 (0.92) 0.20 (1.2) 3.9 (0.08)2
Word CLASSES 0.11 (0.83) 0.18 (1.3)
Expressive language (CELF-IIIR)1 Formulating sentences 0.02 (0.99) 0.03 (1.1) 0.87 (0.37)2
Rapid automatic naming (CELF-IIIR)1 Colors – time to complete 0.30 (0.96) 0.15 (0.96) 0.32 (0.59)2
Shapes – time to complete 0.11 (1.22) 0.04 (0.70)
Colors + shapes – time to complete3 0.12 (1.29) 0.14 (0.69)
XLID, X-linked intellectual disability; ANOVA, analysis of variance; VMPAC, Verbal Motor Production Assessment for Children.
1Full protocol completed by n = 8 ZDHHC9 cases, n = 5 XLID controls; study-normalized Z scores.
2Repeated Measures analysis for Domain, Covarying for FSIQ.
3Not completed by n = 2 ZDHHC9 subjects due to severe impairment on task.
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comparisons. WM reductions were maximal in the body
of the corpus callosum, extending into the temporal lobes
bilaterally. There were no significant regions of relative
WM increase for ZDHHC9 cases.
Comparison of region-of-interest measurements (Fig. 5)
was consistent with automated VBM analysis. On average,
corpus callosum cross-sectional area was reduced by 52%
in ZDHHC9 cases versus controls, thalamic volume by
28.8% on left and 14.9% on right, caudate volume by
15.2% on left and 16.5% on right, and putamen volume
by 26.2% on left and 26.0% on right. Cross-sectional area
of the corpus callosum was significantly reduced in abso-
lute values (Mann–Whitney U P = 0.001), relative to
intracranial volume (P = 0.001), and relative to global
WM (P = 0.001), with no outliers and a narrow distribu-
tion of values within the ZDHHC9 group. Repeated
measures ANOVA was used to compare bilateral tha-
lamic, caudate and putamen volumes, covarying for age
and total GM. This confirmed a highly significant differ-
ence between groups (F1,11 = 29.7, P < 0.001), with no
interaction between group and structure (F2,22 = 2.28,
P = 0.13), or group and hemisphere (F1,11 = 2.6,
P = 0.13).
Discussion
This study demonstrates that genetic diagnosis in neuro-
developmental disorders, including intellectual disability
Figure 2. Attention performance in males with ZDHHC9 mutations and ability-matched X-linked intellectual disability (XLID) controls. (A) Visual
attention tasks, omission errors (one minus hit rate). (B) Visual attention tasks, commission errors (false alarms and anticipatory responses).
Figure 3. Magnetic resonance imaging for males with ZDHHC9 mutations. T1-weighted MRI (midsagittal slice) for eight males with ZDHHC9
mutations. Scans are ordered by chronological age at the time of MRI image acquisition. *Clinically acquired scans. #Case number in Table S1.
6 ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
ZDHHC9 Phenotype K. Baker et al.
and common childhood seizure disorders, will have
enhanced prognostic value and therapeutic relevance
when coupled to multimethod phenotyping. Specifically,
we have observed association between a recurrent
X-linked cause of ID, focal seizures with similarity to the
RE spectrum, and long-term linguistic and nonlinguistic
deficits. Unlike the idiopathic (mixed etiology) RE popu-
lation where cognitive outcomes are variable and neuro-
anatomical differences are either subtle or nonapparent,
ZDHHC9 mutations are associated with relatively homo-
geneous cognitive and neuroanatomical abnormalities,
highlighting a novel developmental pathway for future
exploration.
Ascertainment of ZDHHC9 cases was via genetic
screening of an XLID cohort, a strategy with inherent
benefits and limitations. Retrospective documentation of
epilepsy phenotypes was not comprehensive and EEG
recordings from the time of active epilepsy could not be
traced for all cases. Cognitive and behavioral comparisons
are less informative across a wide age range. Pooling of
phenotype data from individuals with and without cur-
rent seizures, and from individuals with and without cur-
rent antiepileptic medication may introduce confounding
factors which can only be addressed in a larger study.
Despite these limitations and potential confounding fac-
tors, results were consistent across the study group. We
find a higher degree of consistency in neurological and
cognitive characteristics than in physical characteristics
associated with ZDHHC9 mutations – only three out of
five reported families include individuals with skeletal
features reminiscent of marfanoid habitus, whereas all
families include individuals with epilepsy, oromotor
impairments, intellectual disability, and abnormal corpus
callosum; neurocognitive features more reliably segregate
with mutations within families than does dysmorpholo-
gy.3,29 In general, systematic phenotyping of neurological
and cognitive functions may assist interpretation of
genomic test results more reliably than physical dysmor-
phology in neurodevelopmental disorders.
Epilepsy prevalence amongst males with ZDHHC9
mutations was at least three times that expected for ID
overall and seven times that expected for mild ID,30 sig-
nificantly exceeding prevalence amongst comparison sub-
jects with XLID. The reported ictal phenomena and
natural history amongst ZDHHC9 cases suggest suscepti-
bility to focal seizures sharing features with RE, with a
range of seizure severity in keeping with observations
across the idiopathic RE spectrum including previous
family studies.7,31 Childhood seizures associated with cen-
trotemporal spikes on EEG were recently reported for one
further male with a ZDHHC9 truncating mutation, pro-
viding further independent evidence for this association.29
With one exception, age of onset and offset of seizures
amongst ZDHHC9 mutations cases was in keeping with
the typical maturational profile of RE. The identification
of a single ZDHHC9 mutation case with focal seizures
during adulthood could reflect different pathophysiology
of epilepsy in the ZDHHC9 group versus idiopathic RE,
or underreporting of late seizures in individuals suscepti-
ble to RE, or an unrelated pathology in this case. Where
EEG data were available for review, neurophysiological
features were in keeping with an RE spectrum disorder,
with variable interictal phenomena similar to observations
in the idiopathic population.7 For two adult cases where
neurophysiological data were no longer available, local cli-
nician evaluation of clinical history and EEG at the time
of active seizures had led to diagnosis and management
of an RE spectrum disorder. In future prospective studies,
acquisition of sleep EEG would be desirable to demon-
strate sleep activation of epileptiform discharges,
Figure 4. Voxel-based morphometry. Comparison of regional volumetric differences between males with ZDHHC9 mutations (n = 7) and age-
matched male controls (n = 7). Background = mean normalized segmented image for all study participants. (A) Regional gray matter reductions;
red = ZDHHC9 < controls (P < 0.05FWE), blue = ZDHHC9 < controls (P < 0.001uncorrected). (B) Regional white matter reductions;
red = ZDHHC9 < controls (P < 0.05FWE), blue = ZDHHC9 < controls (P < 0.001uncorrected).
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reduction in mu rhythms and muscle artifact, and model-
ing of dipole sources.
It is highly unlikely that one-to-one relationships will
ever be established between genetic etiologies, electro-
physiological abnormalities and clinical epilepsy syn-
dromes, as illustrated by recent identification of GRIN2A
mutations, DEPCD5 mutations and 16p11.2 duplications
across a number of focal epilepsies and epilepsy aphasia
syndromes.32–35 We suggest that ZDHHC9 mutation is
associated with susceptibility to focal seizures, but at this
point cannot be more precise about the range of electro-
clinical phenotypes that may be associated with muta-
tions in this gene. This issue can only be addressed via
empirical investigation to establish the rates of ZDHHC9
mutations amongst individuals ascertained for different
epilepsy syndromes.
Having detected the unexpectedly high frequency of
focal epilepsy amongst males with ZDHHC9 mutations,
we posed the hypothesis that specific cognitive deficits
showing similarity to idiopathic RE might differentiate
ZDHHC9 from other causes of XLID. The hypothesis was
supported: expressive communication, particularly oro-
motor control and fluent speech production, was a prom-
inent area of difficulty for ZDHHC9 cases, consistent with
previous observations of verbal dyspraxia and speech pro-
cessing disorders in familial and sporadic RE.8,10,36,37 The
standardized VMPAC assessment, rated blind to genetic
diagnosis, highlighted deficits in speech sound production
and nonspeech movements such as control of tongue
movements and orolingual sequences, consistent with
independent clinical reports of oral movement abnormali-
ties in two ZDHHC9 mutation cases.29 We also observed
differences between the ZDHHC9 and XLID comparison
groups on measures of nonlinguistic visual attention, with
the ZDHHC9 group showing higher rates of false alarm
errors, suggestive of impairment to inhibitory control
mechanisms. A very similar result – increased commission
errors but not omission errors on a Go/NoGo task – has
been reported for children with RE14 but not at-risk sib-
lings,8 suggesting a relationship between rolandic seizure
activity and the development of attentional control
networks. Cognitive impairments amongst the ZDHHC9
group were present irrespective of overt seizure history,
were present prior to the onset of overt seizures, and were
persistent many years after seizure remission, as recently
documented for idiopathic RE.12
An important caveat is that cognitive deficits in males
with ZDHHC9 mutations were more uniform than previ-
ously observed in RE and occur on a background of mild
to moderate ID. There are several possible explanations
for the higher degree of comorbidity between seizure sus-
ceptibility and cognitive impairments amongst males with
ZDHHC9 mutations as compared to idiopathic RE.
Firstly, impairments may reflect an etiology-specific devel-
opmental pathway, overlapping with some but not all
individuals with RE. Around one-third of idiopathic RE
cases have a speech processing disorder,10 and this subset
of the RE population may share pathophysiology with
ZDHHC9 at the levels of molecular, cellular or neural net-
work mechanisms. Alternatively, observed differences
between the genetic and idiopathic populations may
reflect methodological differences between studies. Ascer-
tainment for XLID in the current study may have intro-
duced bias toward cognitive comorbidities, and exclusion
of individuals with ID from studies of BECTS will have
resulted in the opposite bias. Nevertheless, the choice of
Figure 5. Region-of-interest measurements. (A) Example tracings of
subcortical structures at an equivalent axial level on T1-weighted
imaging for a single ZDHHC9 mutation case and their age-matched
control. Structures were traced from inferior to superior slices
according to predefined landmarks to capture entire volumes. Pale
blue = left caudate, dark blue = right caudate, green = left putamen,
red = right putamen, pink = left thalamus, yellow = right thalamus.
(B) Quantification of subcortical volumes for males with ZDHHC9
mutations and healthy age-matched controls, adjusted for age and
total gray matter volume.
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an ability-matched XLID comparison group in the current
study, rather than reliance on general population stan-
dardization, has enabled specific deficits to be highlighted.
As a first step toward identifying mechanisms underly-
ing the ZDHHC9-associated neurocognitive phenotype we
obtained structural MRI data for all but the most severely
intellectually impaired case and identified consistent neu-
roanatomical abnormalities. Quantitative analysis revealed
focal GM abnormalities within subcortical structures,
maximal in the thalamus. Thalamic abnormalities have
not previously been associated with RE, but have been
detected in other pediatric epilepsy syndromes.38,39
Subcortical abnormalities are also the hallmark of inherited
speech motor disorder caused by FOXP2 mutations.40 In
addition, we and others have observed hypoplasia of the
corpus callosum (generalized or segmental) to be a very
consistent finding in ZDHHC9 cases, at every age from
early childhood to midadulthood.29 Hypoplasia of the
corpus callosum has only rarely been reported in idio-
pathic RE41 however recent application of diffusion-
weighted imaging has highlighted inter-hemispheric
changes that correlate with duration of RE and with cog-
nitive impairments,42 suggesting possible convergence
between severe, homogeneous structural differences in
ZDHHC9 and more subtle differences in a proportion of
the idiopathic RE population. In the adult human brain,
ZDHHC9 expression is restricted to the globus pallidus,
ventral thalamus and WM, with low expression through-
out the cerebral cortex,43 convergent with observed struc-
tural abnormalities in ZDHHC9 mutation cases.
Developmental transcriptome data indicate regionally-spe-
cific and temporally-specific regulation of ZDHHC9
expression, with thalamic expression being maximal dur-
ing antenatal life, and striatal expression increasing to
maximal levels during adulthood (http://brainspan.org/).
One explanation for the differences between neuroi-
maging findings in ZDHHC9 cases and idiopathic RE
could be the low IQ of the case group-features could be
nonspecific observations associated with ID, not related
to etiology or specific cognitive phenotype. In keeping
with this proposal, the cross-sectional area of the corpus
callosum correlated with IQ in a follow-up study of pre-
term infants44 and a similar relationship has been
observed in the general population.45 However, in two
genetic syndromes with similar IQ reductions to the
ZDHHC9 group, we observed age-appropriate callosal
area or relative callosal enlargement, indicating that callo-
sal hypoplasia is not a universal abnormality in ID.46,47
Thinning of the corpus callosum and especially of poster-
ior connections between temporal cortices appears to be a
common observation amongst neurodevelopmental disor-
ders with prominent expressive language impairment,
whether due to genetic cause, for example ARID1B48, or
nongenetic cause, for example prematurity.49 Hence we
speculate that both callosal and subcortical abnormalities
in the ZDHHC9 case group reflect disruptions to develop-
mental connectivity convergent with other language-
impaired populations.
The consequences of ZDHHC9 loss-of-function for
neuronal excitability and maturation of subcortical–corti-
cal systems have yet to be established. Regulators of neu-
ronal excitability known to be palmitoylated include the
voltage-gated sodium channel50 and BK channels.51 In
addition, palmitoylation regulates the synaptic targeting
of PSD-95, a key component of the postsynaptic scaffold-
ing apparatus which regulates NMDA receptor availabil-
ity.52,53 ZDHHC9 may be an informative single gene
model for investigation of activity-dependent network
maturation relevant to epileptogenesis, speech-motor
function and higher order cognitive development.
For individuals diagnosed with ZDHHC9 mutations,
results of this study have prognostic significance since
epilepsy can be anticipated and support can be targeted
to promote expressive communication skills. For the RE
population, genetic testing for ZDHHC9 and other mono-
genic causes may yield further diagnoses with potential to
explain variability in cognitive outcomes. In time, pro-
spective developmental comparisons between different
monogenic causes of RE spectrum disorders may be
informative of distinct neurodevelopmental trajectories,
reflecting molecular pathways which may be amenable to
therapeutic modification.
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